Hemophilia News and Research

RSS

Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

...

27 Jan 2014

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.

From Novo Nordisk 21 Jan 2014

Crozer-Keystone Health System wins 2013 Foster G. McGaw Prize for Excellence in Community Service

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Crozer-Keystone Health System in Delaware County, Pa. is the recipient of the 2013 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.

From Baxter International Inc. 16 Jan 2014

Study shows wide-ranging variation in patterns of X chromosome inactivation in female mice

Producing brightly speckled red and green snapshots of many different tissues, Johns Hopkins researchers have color-coded cells in female mice to display which of their two X chromosomes has been made inactive, or “silenced.”

10 Jan 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life.

9 Jan 2014

Nociceptin in brain naturally moderates effects of stress

Collaborating scientists at The Scripps Research Institute (TSRI), the National Institutes of Health (NIH) and the University of Camerino in Italy have published new findings on a system in the brain that naturally moderates the effects of stress.

8 Jan 2014

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Baxter International Inc. today announced completion of CE marking in Europe for the VIVIA hemodialysis system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy.

From Baxter International Inc. 20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease.

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

CHOP scientist receives 2013 E. Donnall Thomas Prize for scientific, clinical research in hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia (CHOP) was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology (ASH) at its annual meeting on Dec. 9 in New Orleans.

15 Dec 2013

CHOP scientist receives 2013 E. Donnall Thomas Prize for research in bleeding disorder hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology at its annual meeting on Dec. 9 in New Orleans.

14 Dec 2013

Researchers discover new therapeutic approach for hemophilia

Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world.

12 Dec 2013

Understanding long-term clinical stability in hemophilia patients living with HIV

People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

12 Dec 2013

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

11 Dec 2013

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A.

From Baxter International Inc. 11 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Biogen Idec announced today that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application (BLA) for ALPROLIX, the company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.

2 Dec 2013